Objective: Quality of life (QoL) following autologous breast reconstruction has been found to be higher compared to alloplastic breast reconstruction. However, evaluating QoL is complex as it is influenced by various factors, including patient characteristics and treatment types. Previous studies comparing QoL between reconstruction techniques have not sufficiently addressed baseline differences between patient groups, some of which contribute to indication bias. Using an alternative approach to identify the confounders, this study aimed to evaluate which factors affect the patient satisfaction and QoL after alloplastic or autologous reconstruction, with follow-up extending up to 3 years post-surgery. Method: QoL and satisfaction were measured using the Breast-Q preoperatively and after breast reconstruction (post-BR) at 6 weeks, 6 months, 1 year, and 3 years. General and mental health were measured using the SF-36 and the HADS. A generalized linear mixed model was utilized to assess which factors confound the relationship between reconstruction technique and Breast-Q scores. Results: Factors contributing to the disparity in Breast-Q scores between autologous and alloplastic breast reconstruction varied across Breast-Q subscales. Autologous breast reconstruction patients consistently reported higher “Satisfaction with Breasts” and “Physical Well-being,” while the minimal important differences in “Psychosocial” and “Sexual Well-being” were lost after adjustment for confounding factors. Conclusion: This study confirms that even when adjusted for confounders, scores on two QoL subscales autologous breast reconstruction patients score significantly higher over time. Although autologous reconstruction remained superior regarding “Satisfaction with Breasts,” scores decreased in autologous reconstruction patients when they were depressed at baseline, underwent radiotherapy, had a history of breast cancer, or faced major complications.

After mastectomy, 13–69.5% of patients opt for breast reconstruction (BR) [1‒4]. BR has shown to play a significant role in restoring their physical and emotional well-being [5‒9]. Choosing between autologous (using the patient’s own tissue) and alloplastic (using implants) BR is a major decision for the patient. This choice depends on factors such as patient preferences, surgical suitability, health, body type, and cosmetic concerns [10].

Recent studies have consistently shown higher patient satisfaction and improved QoL following autologous BR [9‒19]. However, none of these studies adjusted for differences in baseline characteristics between groups. For example, higher BMI is required for autologous reconstruction for sufficient flap volume. And in cases of required adjuvant radiotherapy, in the Netherlands this is never administrated after autologous reconstruction, whereas in the alloplastic group, radiation can take place after BR. Consequently, many factors lead to indication bias in women seeking BR, which complicates evaluating patient satisfaction and QoL between various BR techniques.

This study investigates patient satisfaction and QoL over 3 years following BR, focusing on how baseline characteristics and treatment factors influence these outcomes. By adjusting for confounding factors, we aim to determine the true effect of the reconstruction technique on satisfaction and QoL.

The current study is a follow-up study of a previously published prospective longitudinal multi-centre cohort study, adding two additional follow-up timepoints [19]. Women over the age of 18 from three hospitals in the northern part of the Netherlands completed questionnaires at 5 timepoints: preoperatively and post-operatively at 6 weeks, 6 months, 1 year, and 3 years. Indication for mastectomy could be either therapeutic or prophylactic. A resume of the surgical course of every patient was made to investigate the total duration of the BR and to place the scores into the proper perspective, using the last intervention of the reconstruction as endpoint. Written informed consent was obtained from the patients before inclusion. The study was approved by the Medical Ethics Committee (2010.191).

Outcome

Our primary outcomes were the following Breast-Q subscales: “Satisfaction with Breasts,” “Psychosocial,” “Sexual,” and “Physical Well-being” over time. The Dutch version of the Breast-Q reconstruction module is a validated, reliable, and reproducible questionnaire that assesses patient satisfaction and QoL after reconstructive surgery [20‒23]. Each Breast-Q scale is scored and converted into scores ranging from 0 to 100 and the minimal important difference is reported as 4 points [21, 22].

Potential Confounders

Online supplementary Table 1 (for all online suppl. material, see https://doi.org/10.1159/000543677) lists the patients, disease and treatment baseline characteristics, which were considered as potential confounders. The age of participants was recorded in years and the BMI was calculated as kg/m2. Smoking status was noted as either “yes” or “no.” (Neo-)adjuvant therapies included radiotherapy, chemotherapy, and hormonal therapy. Comorbidities included hypertension, hypothyroidism, pulmonary disease, diabetes, and rheumatic disease. BR was either unilateral or bilateral and either performed immediately after mastectomy (immediate) or later (delayed). Complications were scored according to the Clavien-Dindo classification and were divided into 1–2 versus 3 or higher [24]. Two questionnaires were included for baseline measurement of overall well-being. The SF-36 covers eight domains of physical and emotional aspects giving a total score of physical and mental health with a minimally important difference of 5 points [25]. The HADS is specialized in detecting symptoms of anxiety and depression, categorized as normal (0–7) or abnormal (8–21) and has a minimally important difference of 1.5 points [26].

Power Calculation

The sample size was calculated for the initial study [20]. As the research question was different, a new post hoc sample size calculation was performed using the linear multiple regression model in G*Power software [27]. The standard deviation of the “Satisfaction with Breasts” was used and the assumption that autologous BR scores 11 points higher than alloplastic BR 36 months after surgery. Post hoc power calculations gave a power of 84%, given an alpha of 0.05, a sample size of 35 per group, testing 12 factors, and an effect size of 0.32.

Statistical Analysis

Using descriptive statistics, we described the demographic characteristics, and preoperative clinical data, stratified by reconstruction technique. The two groups were compared regarding baseline characteristics by using Student-t test, Mann-Whitney U test, or chi-square test, depending on type and distribution of the data. The mean Breast-Q scores per subscale were plotted stratified by reconstruction technique, showing the 5 assessments over time. The characteristics and scores of the dropouts were analysed to evaluate potential bias. When patients missed two or more assessments, they were defined as dropouts.

Linear mixed models were used to test the association between the reconstruction technique and Breast-Q scales. For each Breast-Q scale, two models were built to evaluate the differences of BR technique on QoL. “The original model” is the model used in most published studies; identification of confounders is based on literature and by assessing the AIC and log likelihood. This model is built for “Satisfaction with Breasts” and implemented to all Breast-Q subscales [20, 28]. The “adjusted model” was created for each Breast-Q scale separately. The confounders were identified by their influence on the effect size of reconstruction technique on QoL.

To create the adjusted model, our starting point included the most basic factors such as “autologous” versus “alloplastic BR,” “time,” and “preoperative baseline.” First, an additional variable was included: “BR technique x time” to evaluate if the difference in the Breast-Q subscales outcomes changes over time. Second, the analysis incorporated confounding factors making the effect size for BR technique on QoL change for ≥5% without compromising the model fit. All tested confounders are listed in online supplementary Table 1. Statistical analysis is performed using IBM SPSS Statistics for Windows (version 28.0) (IBM Corp., Armonk, NY).

In the 3 years follow-up, 37 out of the 76 patients (49%) who underwent alloplastic BR still participated in this study. For the autologous BR, this figure was 38 of the 63 (60%). See Figure 1 for a flowchart and overview of the patients participating at each timepoint per BR technique. Comparing patients who participated at all timepoints to dropouts showed no differences between the groups for patients’ characteristics as well as Satisfaction with Breasts score (online suppl. Tables 2, 3).

Fig. 1.

Flowchart of filled in Breast-Q “Satisfaction of Breasts” questionnaire on different timepoints.

Fig. 1.

Flowchart of filled in Breast-Q “Satisfaction of Breasts” questionnaire on different timepoints.

Close modal

Surgical Trajectories

For autologous BR, 83% of the patients had additional operations such as asymmetry corrections, dogear corrections, and nipple reconstruction (either surgical and/or by tattooing). Within 2 years after the initial BR surgery, 89% of the women had completed their reconstruction, increasing to 95% 3 years after reconstruction.

Alloplastic reconstruction contained one-stage or two-stage reconstruction with secondary fine-tuning when needed (asymmetry or dogear corrections), change of the tissue expander for an implant in the two-stage group, followed by nipple reconstruction and/or tattooing when desired. In this group, 89% had more than one surgery, 90% of the patients had completed their BR after 2 years, and 97% after 3 years. Length of the surgical path was quite similar (14.3 vs. 13.7 months; online suppl. Table 4). Surgical complications grade III occurred significantly more in the autologous reconstruction group (online suppl. Table 5).

Patient and Treatment Characteristics

There were significant differences in patient and treatment characteristics between the participants in the alloplastic and autologous BR groups (Table 1). The autologous group was notably older (p = 0.029), had a higher average BMI (p < 0.001), less gene mutations (21% vs. 41%; p = 0.013), and more delayed BR (71% vs. 37%; p < 0.001). The timing of radiotherapy varied significantly between the groups (p < 0.001). Preoperative radiotherapy was more commonly given in the autologous BR group compared to the alloplastic BR group (43% vs. 9%). In contrast, no radiotherapy was administered after autologous BR, while 9% received post-surgery radiotherapy after alloplastic BR (p < 0.001). The time between chemotherapy and BR was longer in the autologous group (p = 0.009), whereas immediate pre-BR and post-BR chemotherapy was more common in the alloplastic group (p < 0.001). Furthermore, women obtained for autologous BR exhibited significant higher preoperative scores on the SF-36 (74 vs. 68) and experienced fewer symptoms of anxiety compared to those undergoing alloplastic BR (19 vs. 42) (p = 0.015, p = 0.002, respectively).

Table 1.

Patient and treatment characteristics per reconstruction group

CharacteristicsAlloplastic, n (%)Autologous, n (%)p value#
Participants 
 Total underwent reconstruction 76 (55) 63 (45) 0.240 
Age, years 
 Mean (SD) 47 (11) 49 (9) 0.029 
BMI, kg/m2 
 Median (IQR) 26 (19–33) 27 (23–32) <0.001 
Smoking 
 Yes 16 (21) 1 (2) <0.001* 
Uni-/bilateral   0.334 
 Unilateral reconstruction 44 (58) 42 (67)  
 Bilateral reconstruction 31 (41) 21 (33)  
Reconstruction indication   0.164 
 Preventive mastectomy 26 (34) 15 (24)  
 Oncological mastectomy 49 (64) 48 (76)  
Gene mutation 
Yes 31 (41) 13 (21) 0.013* 
  BRCA1 14 
  BRCA2 15 
  Othera 
  Unknown, or tested negative 46 (61) 51 (81) 
Reconstruction timing   <0.001* 
 Immediate reconstruction 47 (62) 18 (29)  
 Delayed reconstruction 28 (37) 45 (71)  
Reconstruction technique 
 One-stage reconstructionb 25 (33) na - 
 Two-stage reconstructionc 51 (67)   
Radiotherapy   0.001*1 
 Preoperative radiotherapy 7 (9) 27 (43)  
 Post-operative radiotherapy 7 (9) 0 (0)  
Chemotherapy   0.009*2 
 Chemotherapy in the past 8 (11) 28 (44)  
 Preoperative chemotherapy 10 (13) 6 (10)  
 Post-operative chemotherapy 14 (18) 2 (3)  
Hormonal therapy 
 Hormonal therapy 27 (36) 29 (46) 0.162 
Comorbidities   0.728 
Yes 27 (36) 17 (27)  
  Cardiovascular disease 13  
  Hypothyroidism  
  Pulmonary disease  
  Diabetes  
  Rheumatic disease  
SF-36 total mean (SD)d 
 Preoperative (n = 75 all, 63 aut) 68 (17) 74 (18) 0.015 
 Six weeks (n = 53 all, 50 aut) 57 (17) 61 (16) 0.306 
 Six months (n = 49 all, 49 aut) 68 (18) 77 (16) 0.021 
 One year (n = 43 all, 39 aut) 76 (17) 76 (15) 0.697 
 Three years (n = 37 all, 38 aut) 77 (19) 74 (19) 0.449 
Anxietye 
 Preoperative (n = 74 all, 63 aut) 42 (57) 19 (30) 0.002 
 Six weeks (n = 53 all, 50 aut) 15 (28) 9 (18) 0.216 
 Six months (n = 49 all, 48 aut) 11 (22) 11 (23) 0.956 
 One year (n = 43 all, 38 aut) 7 (16) 9 (24) 0.404 
 Three years (n = 35 all, 38 aut) 5 (14) 9 (24) 0.308 
Depressionf 
 Preoperative (n = 74 all, 63 aut) 26 (35) 20 (32) 0.675 
 Six weeks (n = 53 all, 50 aut) 16 (31) 9 (18) 0.149 
 Six months (n = 49 all, 48 aut) 15 (31) 5 (10) 0.014 
 One year (n = 43 all, 38 aut) 5 (12) 4 (11) 0.875 
 Three years (n = 35 all, 38 aut) 1 (3) 5 (13) 0.109 
CharacteristicsAlloplastic, n (%)Autologous, n (%)p value#
Participants 
 Total underwent reconstruction 76 (55) 63 (45) 0.240 
Age, years 
 Mean (SD) 47 (11) 49 (9) 0.029 
BMI, kg/m2 
 Median (IQR) 26 (19–33) 27 (23–32) <0.001 
Smoking 
 Yes 16 (21) 1 (2) <0.001* 
Uni-/bilateral   0.334 
 Unilateral reconstruction 44 (58) 42 (67)  
 Bilateral reconstruction 31 (41) 21 (33)  
Reconstruction indication   0.164 
 Preventive mastectomy 26 (34) 15 (24)  
 Oncological mastectomy 49 (64) 48 (76)  
Gene mutation 
Yes 31 (41) 13 (21) 0.013* 
  BRCA1 14 
  BRCA2 15 
  Othera 
  Unknown, or tested negative 46 (61) 51 (81) 
Reconstruction timing   <0.001* 
 Immediate reconstruction 47 (62) 18 (29)  
 Delayed reconstruction 28 (37) 45 (71)  
Reconstruction technique 
 One-stage reconstructionb 25 (33) na - 
 Two-stage reconstructionc 51 (67)   
Radiotherapy   0.001*1 
 Preoperative radiotherapy 7 (9) 27 (43)  
 Post-operative radiotherapy 7 (9) 0 (0)  
Chemotherapy   0.009*2 
 Chemotherapy in the past 8 (11) 28 (44)  
 Preoperative chemotherapy 10 (13) 6 (10)  
 Post-operative chemotherapy 14 (18) 2 (3)  
Hormonal therapy 
 Hormonal therapy 27 (36) 29 (46) 0.162 
Comorbidities   0.728 
Yes 27 (36) 17 (27)  
  Cardiovascular disease 13  
  Hypothyroidism  
  Pulmonary disease  
  Diabetes  
  Rheumatic disease  
SF-36 total mean (SD)d 
 Preoperative (n = 75 all, 63 aut) 68 (17) 74 (18) 0.015 
 Six weeks (n = 53 all, 50 aut) 57 (17) 61 (16) 0.306 
 Six months (n = 49 all, 49 aut) 68 (18) 77 (16) 0.021 
 One year (n = 43 all, 39 aut) 76 (17) 76 (15) 0.697 
 Three years (n = 37 all, 38 aut) 77 (19) 74 (19) 0.449 
Anxietye 
 Preoperative (n = 74 all, 63 aut) 42 (57) 19 (30) 0.002 
 Six weeks (n = 53 all, 50 aut) 15 (28) 9 (18) 0.216 
 Six months (n = 49 all, 48 aut) 11 (22) 11 (23) 0.956 
 One year (n = 43 all, 38 aut) 7 (16) 9 (24) 0.404 
 Three years (n = 35 all, 38 aut) 5 (14) 9 (24) 0.308 
Depressionf 
 Preoperative (n = 74 all, 63 aut) 26 (35) 20 (32) 0.675 
 Six weeks (n = 53 all, 50 aut) 16 (31) 9 (18) 0.149 
 Six months (n = 49 all, 48 aut) 15 (31) 5 (10) 0.014 
 One year (n = 43 all, 38 aut) 5 (12) 4 (11) 0.875 
 Three years (n = 35 all, 38 aut) 1 (3) 5 (13) 0.109 

na, not applicable to autologous group; all, alloplastic; aut, autologous.

#Student-t tests were applied on continuous variables or in case of non-normally distributed variables the Mann-Whitney U test and chi-square tests on categorical variables.

*Autologous BR is not performed at this study hospital.

aOther: 1 patient with a BRCA1 and BRCA2 mutation, 1 patient with CHECK2 mutation.

bSix were treated with additional latissimus dorsi flap.

cOne patient was treated with additional latissimus dorsi flap.

dSF-36 total score.

eHADS anxiety score 8–21.

fHADS depression score 8–21.

*Bold/italic: significant with p < 0.05.

#Preoperative/post-operative in terms of the reconstruction not in terms of the mastectomy.

*1Preoperative + post-operative radiotherapy compared between groups.

*2Preoperative + post-operative chemotherapy compared between groups.

“Original Model” for All Breast-Q Subscales: Autologous versus Alloplastic BR

Patients in the autologous group scored higher on “Satisfaction with Breasts,” “Psychosocial Well-being,” “Physical Well-being,” and “Sexual Well-being” when adjusted for age, time post-surgery, baseline score, BMI, radiotherapy, immediate versus delayed BR, SF-36 scores, and anxiety (p < 0.001, p = 0.029, p = 0.090, p = 0.036, and p = 0.019, respectively) (Tables 2-5, right column).

Table 2.

Summary of the two generalized mixed models made for Breast-Q subscale “Satisfaction with Breasts”

Breast-Q subscale “Satisfaction with Breasts”
original modeladjusted model
β (95% CI)p valueβ (95% CI)p value
Alloplastic BR 11.1 (5.0; 17.1) <0.001 14.8 (6.1; 23.5) <0.001 
Autologous BR 
Time 3.4 (2.0; 4.7) <0.001 3.2 (1.3; 5.0) <0.001 
Auto/allo in time −0.1 (−2.8; 2.7) 0.966 
Baseline (pre-op) 0.04 (−0.1; 0.2) 0.578 0.1 (−0.1; 0.2) 0.484 
Age (years) −0.03 (−0.3; 0.3) 0.869 
BMI −0.6 (−1.3; 0.1) 0.111 
Depression pre-op −4.3 (−10.2; 1.2) 0.153 
Radiotherapy −7.1 (−13.5; −0.7) 0.030 −5.8 (−12.8; 1.2) 0.102 
Immediate BR −5.8 (−12.6; 1.1) 0.098 
SF-36 pre-op 0.2 (0.02; 0.4) 0.026 
Anxiety pre-op 0.8 (−5.5; 7.1) 0.810 
Preventive/BC 2.0 (−5.8; 9.8) 0.604 
Chemo 0.6 (−6.3; 7.6) 0.865 
Complication CD ≥3 −5.2 (−12.7; 2.3) 0.170 
Breast-Q subscale “Satisfaction with Breasts”
original modeladjusted model
β (95% CI)p valueβ (95% CI)p value
Alloplastic BR 11.1 (5.0; 17.1) <0.001 14.8 (6.1; 23.5) <0.001 
Autologous BR 
Time 3.4 (2.0; 4.7) <0.001 3.2 (1.3; 5.0) <0.001 
Auto/allo in time −0.1 (−2.8; 2.7) 0.966 
Baseline (pre-op) 0.04 (−0.1; 0.2) 0.578 0.1 (−0.1; 0.2) 0.484 
Age (years) −0.03 (−0.3; 0.3) 0.869 
BMI −0.6 (−1.3; 0.1) 0.111 
Depression pre-op −4.3 (−10.2; 1.2) 0.153 
Radiotherapy −7.1 (−13.5; −0.7) 0.030 −5.8 (−12.8; 1.2) 0.102 
Immediate BR −5.8 (−12.6; 1.1) 0.098 
SF-36 pre-op 0.2 (0.02; 0.4) 0.026 
Anxiety pre-op 0.8 (−5.5; 7.1) 0.810 
Preventive/BC 2.0 (−5.8; 9.8) 0.604 
Chemo 0.6 (−6.3; 7.6) 0.865 
Complication CD ≥3 −5.2 (−12.7; 2.3) 0.170 

Time is the difference between the post-operative measurements. Age is measured in years at the time of reconstruction. Confounding factors in the “Satisfaction with Breasts” analysis included depression, radiotherapy, mastectomy indication, chemotherapy, and complications. After adjusting for these, women with autologous reconstruction reported higher satisfaction, which remained stable post-operatively. Time since surgery significantly influenced satisfaction.

Table 3.

Summary of the two generalized mixed models made for Breast-Q subscale “Psychosocial Well-being”

Breast-Q subscale “Psychosocial Well-being”
original modeladjusted model
β (95% CI)p valueβ (95% CI)p value
Alloplastic BR 6.7 (0.7; 12.9) 0.031 7.7 (−1.7; 17.2) 0.108 
Autologous BR 
Time 3.6 (2.1; 5.1) <0.001 3.5 (1.6; 5.6) <0.001 
Auto/allo in time 0.001 (−3.0; 3.0) 0.993 
Baseline (pre-op) 0.3 (0.1; 0.5) 0.007 0.3 (0.1; 0.5) 0.009 
Age (years) 0.01 (−0.3; 0.3) 0.971 
BMI −0.5 (−1.3; 0.2) 0.158 −0.4 (−1.2; 0.3) 0.259 
Radiotherapy −7.8 (−14.2; −1.4) 0.018 −8.8 (−15.7; −1.8) 0,015 
Immediate BR −4.5 (−11.8; 2.8) 0.227 −5.0 (−12.3; 2.4) 0.183 
SF-36 pre-op 0.4 (0.3; 0.6) <0.001 0.4 (0.2; 0.6) <0.001 
Anxiety pre-op −0.6 (−7.0; 5.8) 0.851 −0.4 (−6.8; 6.0) 0.895 
Bilateral −2.9 (−9.5; 4.4) 0.470 
Chemo −2.5 (−9.5; 4.4) 0.470 
Breast-Q subscale “Psychosocial Well-being”
original modeladjusted model
β (95% CI)p valueβ (95% CI)p value
Alloplastic BR 6.7 (0.7; 12.9) 0.031 7.7 (−1.7; 17.2) 0.108 
Autologous BR 
Time 3.6 (2.1; 5.1) <0.001 3.5 (1.6; 5.6) <0.001 
Auto/allo in time 0.001 (−3.0; 3.0) 0.993 
Baseline (pre-op) 0.3 (0.1; 0.5) 0.007 0.3 (0.1; 0.5) 0.009 
Age (years) 0.01 (−0.3; 0.3) 0.971 
BMI −0.5 (−1.3; 0.2) 0.158 −0.4 (−1.2; 0.3) 0.259 
Radiotherapy −7.8 (−14.2; −1.4) 0.018 −8.8 (−15.7; −1.8) 0,015 
Immediate BR −4.5 (−11.8; 2.8) 0.227 −5.0 (−12.3; 2.4) 0.183 
SF-36 pre-op 0.4 (0.3; 0.6) <0.001 0.4 (0.2; 0.6) <0.001 
Anxiety pre-op −0.6 (−7.0; 5.8) 0.851 −0.4 (−6.8; 6.0) 0.895 
Bilateral −2.9 (−9.5; 4.4) 0.470 
Chemo −2.5 (−9.5; 4.4) 0.470 

Time is the difference between the postoperative measurements. Age is measured in years at the time of reconstruction. “Psychosocial Well-being” was influenced by radiotherapy, preoperative SF-36 scores, and time since surgery (right column). The adjusted model reduced the difference between autologous and alloplastic BR to a non-significant level.

Table 4.

Summary of the two generalized mixed models made for Breast-Q subscale “Sexual Well-being”

Breast-Q subscale “Sexual Well-being”
original modeladjusted model
β (95% CI)p valueβ (95% CI)p value
Alloplastic BR 6.3 (−0.5; 13.1) 0.067 5.4 (−5.0; 15.8) 0.305 
Autologous BR 
Time 2.4 (0.8; 4.0) 0.003 2.0 (−0.2; 4.2) 0.079 
Auto/allo in time 0.6 (−2.7; 3.9) 0.724 
Baseline (pre-op) 0.5 (0.3; 0.7) <0.001 0.5 (0.3; 0.7) <0.001 
Age (years) −0.3 (−0.6; 0.02) 0.067 
BMI 0.2 (−0.6; 1.1) 0.576 
Radiotherapy −12.0 (−19.2; −4.9) 0.001 −9.7 (−17.6; −1.9) 0.016 
Immediate BR −17.9 (−25.6; −10.2) <0.001 −17.1 (−25.4; −8.8) <0.001 
SF-36 pre-op 0.3 (0.1; 0.5) 0.008 0.2 (0.04; 0.4) 0.018 
Anxiety pre-op −4.5 (−11.7; 2.8) 0.224 −3.0 (−10.3; 4.3) 0.418 
Chemo 3.4 (−4.3; 11.1) 0.384 
BC versus preventive 9.0 (0.1; 17.9) 0.047 
Breast-Q subscale “Sexual Well-being”
original modeladjusted model
β (95% CI)p valueβ (95% CI)p value
Alloplastic BR 6.3 (−0.5; 13.1) 0.067 5.4 (−5.0; 15.8) 0.305 
Autologous BR 
Time 2.4 (0.8; 4.0) 0.003 2.0 (−0.2; 4.2) 0.079 
Auto/allo in time 0.6 (−2.7; 3.9) 0.724 
Baseline (pre-op) 0.5 (0.3; 0.7) <0.001 0.5 (0.3; 0.7) <0.001 
Age (years) −0.3 (−0.6; 0.02) 0.067 
BMI 0.2 (−0.6; 1.1) 0.576 
Radiotherapy −12.0 (−19.2; −4.9) 0.001 −9.7 (−17.6; −1.9) 0.016 
Immediate BR −17.9 (−25.6; −10.2) <0.001 −17.1 (−25.4; −8.8) <0.001 
SF-36 pre-op 0.3 (0.1; 0.5) 0.008 0.2 (0.04; 0.4) 0.018 
Anxiety pre-op −4.5 (−11.7; 2.8) 0.224 −3.0 (−10.3; 4.3) 0.418 
Chemo 3.4 (−4.3; 11.1) 0.384 
BC versus preventive 9.0 (0.1; 17.9) 0.047 

Time is the difference between the post-operative measurements. Age is measured in years at the time of reconstruction. Radiotherapy and preoperative SF-36 scores influenced “Sexual Well-being.” Timing and indication for surgery also played a role: immediate BR was associated with lower sexual well-being compared to delayed BR, and prophylactic surgery patients scored higher than those with cancer-related mastectomies.

Table 5.

Summary of the two generalized mixed models made for Breast-Q subscale “Physical Well-being”

Breast-Q subscale “Physical Well-being”
original modeladjusted model
β (95% CI)p valueβ (95% CI)p value
Alloplastic 6.6 (0.8; 12.3) 0.026 10.1 (2.3; 17.8) 0.011 
Autologous 
Time 3.1 (1.9; 4.5) <0.001 3.9 (2.1; 5.6) <0.001 
Auto/allo in time −1.7 (−4.2; 0.7) 0.168 
Baseline (pre-op) 0.4 (0.2; 0.6) <0.001 0.3 (0.2; 0.4) <0.001 
Age (years) 0.007 (−0.3; 0.3) 0.959 
BMI 0.1 (−0.6; 0.7) 0.877 
Radiotherapy −1.8 (−7.3; 3.7) 0.522 
Immediate BR −0.05 (−5.8; 5.7) 0.987 
SF-36 pre-op 0.03 (−0.1; 0.2) 0.766 
Anxiety pre-op −3.3 (−8.7; 2.1) 0.227 −4.4 (−9.3; 0.5) 0.079 
Comorbidity 1.5 (−3.7; 6.6) 0.573 
Breast-Q subscale “Physical Well-being”
original modeladjusted model
β (95% CI)p valueβ (95% CI)p value
Alloplastic 6.6 (0.8; 12.3) 0.026 10.1 (2.3; 17.8) 0.011 
Autologous 
Time 3.1 (1.9; 4.5) <0.001 3.9 (2.1; 5.6) <0.001 
Auto/allo in time −1.7 (−4.2; 0.7) 0.168 
Baseline (pre-op) 0.4 (0.2; 0.6) <0.001 0.3 (0.2; 0.4) <0.001 
Age (years) 0.007 (−0.3; 0.3) 0.959 
BMI 0.1 (−0.6; 0.7) 0.877 
Radiotherapy −1.8 (−7.3; 3.7) 0.522 
Immediate BR −0.05 (−5.8; 5.7) 0.987 
SF-36 pre-op 0.03 (−0.1; 0.2) 0.766 
Anxiety pre-op −3.3 (−8.7; 2.1) 0.227 −4.4 (−9.3; 0.5) 0.079 
Comorbidity 1.5 (−3.7; 6.6) 0.573 

Time is the difference between the post-operative measurements. Age is measured in years at the time of reconstruction. In the “Physical Well-being” subscale, women who underwent autologous BR had significantly higher with no significant change over time (right column). Adjusting the model for this subscale did not affect the significance of the group difference, but it strengthened the correlation.

Baseline Patient Characteristics Impacting the Difference in Scores of the Breast-Q Subscales of Autologous and Alloplastic Reconstruction: “The Adjusted Model”

Confounding factors identified in the analysis of “Satisfaction with Breasts” were depression, radiotherapy, indication for mastectomy, chemotherapy, and complications (Table 2, right column). Even after accounting for these factors, women undergoing autologous reconstruction consistently reported higher satisfaction with their breasts (B = 14.8 [6.1; 23.5], p < 0.001). The difference in satisfaction remained stable post-operatively (B = −0.1 [−2.8; 2.7], p = 0.966). Time after surgery was influencing the score for all women included (R = 3.2 [1.3; 5.0], p < 0.001).

Adjusting the model for the specific confounders influenced the differences between autologous and alloplastic BR patients, increased the correlation coefficient from 11.1 to 14.8 (Table 2, left and right column), indicating that the autologous BR group scores 14.8 points higher on “Satisfaction with Breasts” than the alloplastic group. “Psychosocial Well-being” was influenced by the administration of radiotherapy (B = −8.8 [−15.7; 1.8], p = 0.015), preoperative SF-36 scores (B = 0.4 [0.2; 0.6], p < 0.001), and time after surgery (B = 3.5 [1.6; 5.6], p < 0.001) (Table 3, right column). The adjusted model diminished the earlier reported difference between autologous and alloplastic BR to a non-significant level (Table 3).

Radiotherapy (R = −9.7 [−17.6; −1.9], p = 0.016) and the preoperative SF-36 (B = 0.2 [0.04; 0.4], p = 0.018) scores also played a role in “Sexual Well-being.” Timing and indication for surgery also played a role; women who underwent immediate BR had significantly lower sexual well-being compared to patients who underwent delayed BR (B = −17.0 [−25.4; −8.8], p < 0.001). Also, women who had prophylactic surgery scored higher on sexual well-being compared to those who had undergone a mastectomy for breast cancer (Table 4, right column). After adjusting the model for this specific subscale, no significant difference between autologous and alloplastic BR remained (Table 4).

In the subscale “Physical Well-being,” scores were significantly higher for women who underwent autologous BR (B = 10.1 [2.3; 17.8], p = 0.011), and this did not significantly change over time (B = −1.7 [−4.2; 0.7], p = 0.168) (Table 5, right column). Adjusting the model for this subscale had no influence on the significance of the difference between the two groups, although it increased the correlation (Table 5).

The plotted Breast-Q scores differences over time for each BR group remained stable and comparable in the post-operative course (Fig. 2). This was confirmed in the (adjusted) model. Integrating the variable describing difference between BR during follow up did not lead to a statistically significant difference. This means that the difference between both groups stayed the same between 6 weeks and 3 years post-operatively (Tables 2-5, right column).

Fig. 2.

Breast-Q subscales scores for alloplastic (blue) and autologous (pink) BR in time. Timepoints are preoperative, 6 weeks, 6 months, 1 year, and 3 years post-operative. Breast-Q subscales: “Satisfaction with Breasts” (a), “Psychosocial Well-being” (b), “Sexual Well-being” (c), and “Physical Well-being” (d).

Fig. 2.

Breast-Q subscales scores for alloplastic (blue) and autologous (pink) BR in time. Timepoints are preoperative, 6 weeks, 6 months, 1 year, and 3 years post-operative. Breast-Q subscales: “Satisfaction with Breasts” (a), “Psychosocial Well-being” (b), “Sexual Well-being” (c), and “Physical Well-being” (d).

Close modal

Increased Correlation between Reconstruction Technique and “Satisfaction with Breasts”

To get more insight in the increased correlation from the original model to the adjusted model, the role of the identified confounders on “Satisfaction with Breasts” were plotted and analysed. This shows that high depression score before surgery significantly decreases the “Satisfaction with Breasts” score after autologous reconstruction, compared to alloplastic reconstruction at timepoint 6 weeks, 6 months and 3 years after reconstruction (p = 0.002, p = 0.011, p = 0.001, and p < 0.001, respectively) (Fig. 3a; Table 6). Without radiotherapy, the satisfaction remains significantly higher after autologous BR, but this difference seems to level after 3 years (p = 0.022, p = 0.019, p = 0.002, respectively; Fig. 3b; Table 6).

Fig. 3.

Satisfaction with Breasts” scores for alloplastic (cold colours) and autologous (warm colours) BR in time. Timepoints are preoperative, 6 weeks, 6 months, 1 year, and 3 years post-operative. Patient characteristics are specified for depression score at baseline (a), radiotherapy treatment (b), history of breast cancer (c), and complications (d).

Fig. 3.

Satisfaction with Breasts” scores for alloplastic (cold colours) and autologous (warm colours) BR in time. Timepoints are preoperative, 6 weeks, 6 months, 1 year, and 3 years post-operative. Patient characteristics are specified for depression score at baseline (a), radiotherapy treatment (b), history of breast cancer (c), and complications (d).

Close modal
Table 6.

Effect of identified confounders on “Satisfaction with Breasts” stratified for BR technique over time

TimepointMean alloMean autop valueMean difference95% CI
No complications: > Clavien-Dindo 3 
 Baseline 61.7 (23.4) 49.4 (16.9) 0.003 12.3 4.2; 20.4 
 Six weeks 50.8 (17.6) 63.8 (12.9) <0.001 −12.9 −19.5; −6.3 
 Six months 58.3 (19.5) 68.7 (18.0) 0.016 −10.4 −18.7; −2.0 
 One year 62.7 (17.0) 78.5 (18.5) <0.001 −15.9 −24.2; −7.5 
 Three years 64.0 (17.5) 72.6 (15.0) 0.037 −8.6 −16.7; −0.6 
Complications: Clavien-Dindo 3 or higher 
 Baseline 49.1 (14.6) 49.4 (15.8) 0.962 −0.3 −12.6; 12.1 
 Six weeks 64.3 (20.0) 58.5 (18.1) 0.557 5.9 −15.9; 27.7 
 Six months 58.0 (12.1) 59.7 (13.1) 0.843 −1.7 −26.0; 23.0 
 One year 48.5 (14.8) 63.3 (20.3) 0.359 −14.8 −69.6; 39.9 
 Three years 38.5 (31.8) 69.8 (19.8) 0.383 −31.3 −234.3; 171.8 
Low/no depression score at baseline 
 Baseline 62.3 (21.5) 49.0 (15.6) 0.001 13.3 5.4; 21.2 
 Six weeks 52.4 (17.1) 64.6 (14.2) 0.002 −12.3 −19.9; −4.6 
 Six months 57.9 (19.5) 70.0 (17.0) 0.012 −12.1 −21.5; −2.7 
 One year 62.3 (16.3) 79.2 (19.7) <0.001 −16.8 −26.4; −7.2 
 Three years 64.5 (18.7) 74.2 (16.3) 0.057 −16.8 −19.8; 0.3 
High depression score at baseline 
 Baseline 55.0 (24.0) 50.1 (18.7) 0.432 5.0 −7.7; 17.7 
 Six weeks 49.7 (17.9) 56.6 (14.1) 0.224 −6.9 −18.3; 4.5 
 Six months 59.1 (17.5) 58.8 (15.8) 0.957 0.3 −18.3; 4.5 
 One year 64.4 (16.6) 66.6 (15.8) 0.756 −2.2 −16.7; 12.3 
 Three years 57.7 (20.1) 67.4 (15.3) 0.221 −9.6 −25.6; 6.3 
Patients who did not receive radiotherapy 
 Baseline 61.6 (21.0) 53.8 (16.8) 0.063 7.8 −0.4; 15.9 
 Six weeks 55.7 (13.3) 64.7 (17.1) 0.035 −9.0 −17.3; −0.7 
 Six months 58.6 (18.5) 70.0 (18.2) 0.019 −11.4 −20.9; −1.9 
 One year 62.9 (17.2) 79.2 (18.7) 0.004 −16.2 −26.8; −5.7 
 Three years 63.6 (19.9) 74.2 (17.5) 0.060 −10.5 −21.6; 0.5 
Radiotherapy given 
 Baseline 53.3 (26.6) 46.0 (16.5) 0.364 7.2 −9.1; 23.6 
 Six weeks 41.5 (26.6) 59.4 (12.2) 0.013 −17.9 −31.7; −4.0 
 Six months 57.2 (22.4) 61.3 (15.9) 0.631 −4.1 −22.9; 14.0 
 One year 58.4 (16.6) 69.6 (20.6) 0.157 −11.1 −26.9; 4.6 
 Three years 59.0 (14.3) 69.6 (15.5) 0.129 −10.6 −24.7; 3.4 
Prophylactic mastectomy 
 Baseline 67.1 (15.9) 64.5 (15.2) 0.607 2.6 −7.7; 12.9 
 Six weeks 55.3 (10.4) 64.2 (21.4) 0.218 −8.9 −23.8; 6.0 
 Six months 55.2 (19.1) 66.2 (18.6) 0.118 −11.1 −25.1; 3.0 
 One year 64.3 (15.6) 76.6 (19.2) 0.084 −12.3 −26.4; 1.8 
 Three years 69.1 (16.3) 77.1 (13.2) 0.208 −8.0 −20.8; 4.8 
Therapeutic mastectomy 
 Baseline 56.7 (25.2) 44.6 (13.9) 0.004 12.1 3.9; 20.3 
 Six weeks 49.7 (15.9) 61.5 (12.1) 0.006 −11.8 −20.2; −3.4 
 Six months 59.6 (18.3) 66.6 (17.1) 0.137 −7.0 −16.2; 2.3 
 One year 62.1 (17.2) 74.9 (20.5) 0.017 −12.7 −23.2; −2.4 
 Three years 57.4 (19.0) 70.1 (17.0) 0.020 12.0 −23.2; −2.4 
TimepointMean alloMean autop valueMean difference95% CI
No complications: > Clavien-Dindo 3 
 Baseline 61.7 (23.4) 49.4 (16.9) 0.003 12.3 4.2; 20.4 
 Six weeks 50.8 (17.6) 63.8 (12.9) <0.001 −12.9 −19.5; −6.3 
 Six months 58.3 (19.5) 68.7 (18.0) 0.016 −10.4 −18.7; −2.0 
 One year 62.7 (17.0) 78.5 (18.5) <0.001 −15.9 −24.2; −7.5 
 Three years 64.0 (17.5) 72.6 (15.0) 0.037 −8.6 −16.7; −0.6 
Complications: Clavien-Dindo 3 or higher 
 Baseline 49.1 (14.6) 49.4 (15.8) 0.962 −0.3 −12.6; 12.1 
 Six weeks 64.3 (20.0) 58.5 (18.1) 0.557 5.9 −15.9; 27.7 
 Six months 58.0 (12.1) 59.7 (13.1) 0.843 −1.7 −26.0; 23.0 
 One year 48.5 (14.8) 63.3 (20.3) 0.359 −14.8 −69.6; 39.9 
 Three years 38.5 (31.8) 69.8 (19.8) 0.383 −31.3 −234.3; 171.8 
Low/no depression score at baseline 
 Baseline 62.3 (21.5) 49.0 (15.6) 0.001 13.3 5.4; 21.2 
 Six weeks 52.4 (17.1) 64.6 (14.2) 0.002 −12.3 −19.9; −4.6 
 Six months 57.9 (19.5) 70.0 (17.0) 0.012 −12.1 −21.5; −2.7 
 One year 62.3 (16.3) 79.2 (19.7) <0.001 −16.8 −26.4; −7.2 
 Three years 64.5 (18.7) 74.2 (16.3) 0.057 −16.8 −19.8; 0.3 
High depression score at baseline 
 Baseline 55.0 (24.0) 50.1 (18.7) 0.432 5.0 −7.7; 17.7 
 Six weeks 49.7 (17.9) 56.6 (14.1) 0.224 −6.9 −18.3; 4.5 
 Six months 59.1 (17.5) 58.8 (15.8) 0.957 0.3 −18.3; 4.5 
 One year 64.4 (16.6) 66.6 (15.8) 0.756 −2.2 −16.7; 12.3 
 Three years 57.7 (20.1) 67.4 (15.3) 0.221 −9.6 −25.6; 6.3 
Patients who did not receive radiotherapy 
 Baseline 61.6 (21.0) 53.8 (16.8) 0.063 7.8 −0.4; 15.9 
 Six weeks 55.7 (13.3) 64.7 (17.1) 0.035 −9.0 −17.3; −0.7 
 Six months 58.6 (18.5) 70.0 (18.2) 0.019 −11.4 −20.9; −1.9 
 One year 62.9 (17.2) 79.2 (18.7) 0.004 −16.2 −26.8; −5.7 
 Three years 63.6 (19.9) 74.2 (17.5) 0.060 −10.5 −21.6; 0.5 
Radiotherapy given 
 Baseline 53.3 (26.6) 46.0 (16.5) 0.364 7.2 −9.1; 23.6 
 Six weeks 41.5 (26.6) 59.4 (12.2) 0.013 −17.9 −31.7; −4.0 
 Six months 57.2 (22.4) 61.3 (15.9) 0.631 −4.1 −22.9; 14.0 
 One year 58.4 (16.6) 69.6 (20.6) 0.157 −11.1 −26.9; 4.6 
 Three years 59.0 (14.3) 69.6 (15.5) 0.129 −10.6 −24.7; 3.4 
Prophylactic mastectomy 
 Baseline 67.1 (15.9) 64.5 (15.2) 0.607 2.6 −7.7; 12.9 
 Six weeks 55.3 (10.4) 64.2 (21.4) 0.218 −8.9 −23.8; 6.0 
 Six months 55.2 (19.1) 66.2 (18.6) 0.118 −11.1 −25.1; 3.0 
 One year 64.3 (15.6) 76.6 (19.2) 0.084 −12.3 −26.4; 1.8 
 Three years 69.1 (16.3) 77.1 (13.2) 0.208 −8.0 −20.8; 4.8 
Therapeutic mastectomy 
 Baseline 56.7 (25.2) 44.6 (13.9) 0.004 12.1 3.9; 20.3 
 Six weeks 49.7 (15.9) 61.5 (12.1) 0.006 −11.8 −20.2; −3.4 
 Six months 59.6 (18.3) 66.6 (17.1) 0.137 −7.0 −16.2; 2.3 
 One year 62.1 (17.2) 74.9 (20.5) 0.017 −12.7 −23.2; −2.4 
 Three years 57.4 (19.0) 70.1 (17.0) 0.020 12.0 −23.2; −2.4 

Former breast cancer patients score lower scores before the actual autologous BR but higher after 6 weeks, 1 year, and 3 years after autologous reconstruction (p = 0.004, p = 0.006, p = 0.017, and p = 0.020) (see Fig. 3c and Table 6). When no or mild complications (Clavien-Dindo <3) occur, autologous reconstruction patients score higher in satisfaction at all timepoints (p = 0.003, p < 0.001, p = 0.016, p < 0.001, p = 0.037) (Fig. 3d; Table 6).

This study examines Breast-Q changes over time following BR. The most important finding of this study is that the difference in “Satisfaction with Breasts” and “Physical Well-being” is not caused by the patient characteristics. It shows that, concerning “Satisfaction with Breasts,” autologous BR is superior to alloplastic BR directly after surgery until 3 years post-operatively. This difference has been found before but was thought to be related to factors such as a higher BMI, a lower prevalence of adjuvant therapy, and no two-stage reconstruction in the autologous group [10, 11, 29, 30]. Our new approach revealed that although BMI influences the overall “Satisfaction with Breasts” scores, it does not influence the difference in satisfaction between autologous and alloplastic BR. We identified baseline depression score, radiotherapy, indication for mastectomy, and Clavien-Dindo 3 or higher complications as important confounding factors [31]. These factors are partly correlated and represent characteristics, which deserve special attention. Preoperative depression is associated with complications and more common after breast cancer [32]. Also, radiotherapy will only be given after definitive breast cancer diagnosis. As all autologous reconstruction patients received RT before reconstruction, the lower score after surgery could be a delayed effect but could also be due to fatigue, or its influence on wound healing [33]. Further research is needed to investigate a possible correlation between these factors.

Another important finding is that the differences in “Psychosocial Well-being” and “Sexual Well-being” can be explained by patient and treatment characteristics. In both subscales, the preoperative baseline, the SF-36 score, and having had radiotherapy changed the correlation coefficient but also significantly influenced the Breast-Q score. In “Sexual Well-being,” women undergoing immediate BR scored preoperatively 17 points higher than women undergoing delayed BR, an important nuance often overlooked in studies lacking preoperative measurements or adopting different research questions and statistical analyses [9, 11, 12, 34]. The studies that included preoperative measurement had a different research question and therefore choose a different statistical analysis [19, 35]. In the majority of previous studies, autologous BR scored higher on “Satisfaction with Breasts” and “Psychosocial,” “Physical,” and “Sexual Well-being” than alloplastic BR. We are the first to correct for patient and treatment characteristics per scale based on their influence on the effect size of BR technique on QoL. Our finding is consistent with a published randomized BR study where women eligible for both techniques were randomized, excluding patients only eligible for one of the two techniques [36]. The findings of this study corroborate ours and also showed that only the difference in satisfaction with breast and physical well-being remains at the end of follow-up, although we reached this conclusion by using statistical analysis method, leaving more inclusive results for the general patient population [36].

None of the Breast-Q subscales showed a meaningful change in scores between the alloplastic and autologous groups between 6 weeks and 3 years, but over time, the overall scores for “Physical,” “Psychosocial Well-being” and “Satisfaction with Breasts” increased. A previous study showed that autologous BR patients still score higher on all Breast-Q scales 9–13 years after BR [29]. For the subscale “Satisfaction with Breasts,” autologous BR is definitely superior; however, our study showed that for the other subscales the outcomes are more nuanced. The earlier found differences over time could be explained by the effect of patient characteristics that are more prevalent in one of two groups, for example, fear for implant rupture, breast implant disease, capsular contracture, or long-term effects of oncological treatment [12, 37‒39]. We observed significantly lower Breast-Q scores preoperatively in most scales in the autologous group. In all Breast-Q scales, the superiority in score for alloplastic reconstruction shifts to autologous between baseline at 6 weeks after surgery. This underlines the difference in baseline characteristics. Alloplastic reconstruction patients mostly underwent immediate BR using tissue expanders and sometimes direct implants while autologous reconstruction surgery is mostly delayed. This explains the high increase in Breast-Q scores for the autologous BR group and the decrease for the alloplastic BR group at 6 weeks post-operatively. It also suggests that the intensity of autologous reconstructive surgery and the physical strain does not negatively influence QoL. Following this suggestion, we could look critically what risk of complications are affordable to choose for autologous reconstruction looking at long-term QoL.

Our study has several strengths. First, the main strength is its prospective nature including preoperative measurements; second, the addition of a 3-year follow-up is highly valuable as approximately 95% of patients have then completed their final reconstruction; third, the adjusted statistical models in which we corrected for patient characteristics; fourth, the use of the SF-36 to incorporate the general health of the patients as a confounding factor; fifth, the translation from the data to practical use [40]; and last, special attention to the inevitable risk of bias by dropouts.

There are also limitations. Due to the COVID-19 pandemic, elective surgeries, such as delayed BR and secondary corrections, were postponed, leading to long waiting lists. This may have resulted in a delayed completion of the surgical course [41, 42]. Analysing the dropouts showed that this had no effect on our results, although it decreased the power of our findings. This effected the possibilities we had in pinpointing the smaller differences. A larger cohort could also look at characteristics as type of mastectomy and degree of ptosis of the initial breasts. Lastly, an important difference between the two reconstruction techniques is the lack of a donor region in case of alloplastic reconstruction. Because the satisfaction with abdomen questionnaire was not applicable for the alloplastic group, this could not be included in the comparison.

Future prospective studies could also include no BR and other forms of BR such as the Goldilocks procedure and full BR using autologous fat transfer as these groups are growing and show different QoL patterns [42‒46]. As this study shows the superiority of QoL for autologous BR despite the complication risk, a study to investigate the criteria for this form of reconstruction could be in place.

Autologous BR stays superior to alloplastic BR when it comes to “Satisfaction with Breasts” and “Physical Well-being,” despite the higher risk of complications and longer recovery time. Patients who suited best for autologous reconstruction are women who needed prophylactic mastectomy, were without depression preoperatively, and had minimal risk of severe complications.

Our findings contribute valuable insights to the ongoing discussion surrounding BR techniques and their implications for patients’ well-being. In the context of shared decision-making, it is crucial for the physician to consider that baseline psychosocial health and sexual well-being, along with patient characteristics, play a significant role in quality of life. Opting for autologous reconstruction does not necessarily guarantee an improvement in all aspects of QoL as we have shown that, if corrected for baseline characteristics, “Psychosocial Well-being” and “Sexual Well-being” subscales were not superior.

We wish to thank all the patients and staff for their contribution to this study.

The study was approved by the Medical Ethics Committee University Medical Center Groningen (2010.191). Written informed consent was obtained from the patients before inclusion.

Paul M. N. Werker is a DMC member for Fidia Ltd, Milan-IT. Renumerations are used for research purposes. Iris L. Holt-Kedde, Nadia Sadok, Irene S. Krabbe-Timmerman, Geertruida H. de Bock, and Grigory Sidorenkov have nothing to disclose.

There are no funding sources to be declared.

I.L.H.-K., N.S., and I.S.K.-T. collected the data. G.B. and G.S. contributed to the analysis and interpretation of the results. I.L.H.-K. and N.S. took the lead in writing the manuscript. P.M.N.W. supervised the whole process. All authors provided critical feedback and helped shape the research, analysis, and manuscript.

The data that support the findings of this study are available from the corresponding author, I.L.H.-K., upon reasonable request.

1.
Jonczyk
MM
,
Jean
J
,
Graham
R
,
Chatterjee
A
.
Surgical trends in breast cancer: a rise in novel operative treatment options over a 12 year analysis
.
Breast Cancer Res Treat
.
2019
;
173
(
2
):
267
74
.
2.
Semple
J
,
Metcalfe
KA
,
Lynch
HT
,
Kim-Sing
C
,
Senter
L
,
Pal
T
, et al
.
International rates of breast reconstruction after prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers
.
Ann Surg Oncol
.
2013
;
20
(
12
):
3817
22
.
3.
O’Halloran
N
,
Lowery
A
,
Kalinina
O
,
Sweeney
K
,
Malone
C
,
McLoughlin
R
, et al
.
Trends in breast reconstruction practices in a specialized breast tertiary referral centre
.
BJS Open
.
2017
;
1
(
5
):
148
57
.
4.
Meyer-Marcotty
MV
,
Hankiss
J
,
Flügel
M
,
Redeker
J
.
Brustrekonstruktionen bei Patientinnen mit Mammakarzinom: Eine Analyse anhand der Daten von 4335 Patientinnen aus 16 Kliniken [Breast reconstruction for patients with breast carcinoma: an analysis based on the data of 4,335 patients from 16 hospitals]
.
Chirurg
.
2007
;
78
(
7
):
637
42
.
5.
Wilkins
EG
,
Cederna
PS
,
Lowery
JC
,
Davis
JA
,
Kim
HM
,
Roth
RS
, et al
.
Prospective analysis of psychosocial outcomes in breast reconstruction: one-year postoperative results from the Michigan breast reconstruction outcome study
.
Plast Reconstr Surg
.
2000
;
106
(
5
):
1014
27
.
6.
Elder
EE
,
Brandberg
Y
,
Björklund
T
,
Rylander
R
,
Lagergren
J
,
Jurell
G
, et al
.
Quality of life and patient satisfaction in breast cancer patients after immediate breast reconstruction: a prospective study
.
Breast
.
2005
;
14
(
3
):
201
8
.
7.
Al-Ghazal
SK
,
Sully
L
,
Fallowfield
L
,
Blamey
RW
.
The psychological impact of immediate rather than delayed breast reconstruction
.
Eur J Surg Oncol
.
2000
;
26
(
1
):
17
9
.
8.
Dean
C
,
Chetty
U
,
Forrest
APM
.
Effects of immediate breast reconstruction on psychosocial morbidity after mastectomy
.
Lancet
.
1983
;
1
(
8322
):
459
62
.
9.
Thorarinsson
A
,
Fröjd
V
,
Kölby
L
,
Ljungdal
J
,
Taft
C
,
Mark
H
.
Long-term health-related quality of life after breast reconstruction: comparing 4 different methods of reconstruction
.
Plast Reconstr Surg Glob Open
.
2017
;
5
(
6
):
e1316
9
.
10.
Dauplat
J
,
Kwiatkowski
F
,
Rouanet
P
,
Delay
E
,
Clough
K
,
Verhaeghe
JL
, et al
.
Quality of life after mastectomy with or without immediate breast reconstruction
.
Br J Surg
.
2017
;
104
(
9
):
1197
206
.
11.
Eltahir
Y
,
Krabbe-Timmerman
IS
,
Sadok
N
,
Werker
PMN
,
De Bock
GH
.
Outcome of quality of life for women undergoing autologous versus alloplastic breast reconstruction following mastectomy: a systematic review and meta-analysis
.
Plast Reconstr Surg
.
2020
;
145
(
5
):
1109
23
.
12.
Santosa
KB
,
Qi
J
,
Kim
HM
,
Hamill
JB
,
Wilkins
EG
,
Pusic
AL
.
Long-term patient-reported outcomes in postmastectomy breast reconstruction
.
JAMA Surg
.
2018
;
153
(
10
):
891
9
.
13.
Miseré
RM
,
van Kuijk
SM
,
Claassens
EL
,
Heuts
EM
,
Piatkowski
AA
,
van der Hulst
RR
.
Breast-related and body-related quality of life following autologous breast reconstruction is superior to implant-based breast reconstruction: a long-term follow-up study
.
Breast
.
2021
;
59
:
176
82
.
14.
Al-Ghazal
SK
,
Fallowfield
L
,
Blamey
RW
.
Comparison of psychological aspects and patient satisfaction following breast conserving surgery, simple mastectomy and breast reconstruction
.
Eur J Cancer
.
2000
;
36
(
15
):
1938
43
.
15.
Retrouvey
H
,
Kerrebijn
I
,
Metcalfe
KA
,
O'Neill
AC
,
McCready
DR
,
Hofer
SOP
, et al
.
Psychosocial functioning in women with early breast cancer treated with breast surgery with or without immediate breast reconstruction
.
Ann Surg Oncol
.
2019
;
26
(
8
):
2444
51
.
16.
Howes
BHL
,
Watson
DI
,
Xu
C
,
Fosh
B
,
Canepa
M
,
Dean
NR
.
Quality of life following total mastectomy with and without reconstruction versus breast-conserving surgery for breast cancer: a case-controlled cohort study
.
J Plast Reconstr Aesthet Surg
.
2016
;
69
(
9
):
1184
91
.
17.
Metcalfe
KA
,
Semple
J
,
Quan
ML
,
Vadaparampil
ST
,
Holloway
C
,
Brown
M
, et al
.
Changes in psychosocial functioning 1 year after mastectomy alone, delayed breast reconstruction, or immediate breast reconstruction
.
Ann Surg Oncol
.
2012
;
19
(
1
):
233
41
.
18.
Cornelissen
AJM
,
Tuinder
SMH
,
Heuts
EM
,
van der Hulst
RRWJ
,
Slatman
J
.
What does a breast feel like? A qualitative study among healthy women
.
BMC Womens Health
.
2018
;
18
(
1
):
82
7
.
19.
Sadok
N
,
Krabbe-Timmerman
IS
,
Buisman
NH
,
van Aalst
VC
,
de Bock
GH
,
Werker
PMN
.
Short-term quality of life after autologous compared with alloplastic breast reconstruction: a prospective study
.
Plast Reconstr Surg
.
2023
;
152
(
4S
):
55
68
.
20.
BREAST-Q version 2.0
. Available from: http://qportfolio.org/wp-content/uploads/2018/12/BREAST-Q-USERS-GUIDE.pdf (Accessed July 1, 2020).
21.
Cano
SJ
,
Klassen
AF
,
Pusic
AL
.
From breast-Q © to Q-score ©: using rasch measurement to better capture breast surgery outcomes. 14th jt int IMEKO TC1, TC7, TC13 symp intell qual meas - theory, educ train 2011
Held Conj with 56th IWK Ilmenau Univ Technol.
2011
; p.
82
94
.
22.
Chu
JJ
,
Tadros
AB
,
Gallo
L
,
Mehrara
BJ
,
Morrow
M
,
Pusic
AL
, et al
.
Interpreting the BREAST-Q for breast-conserving therapy: minimal important differences and clinical reference values
.
Ann Surg Oncol
.
2023
;
30
(
7
):
4075
84
.
23.
Memorial Sloan Kettering Cancer Center
.
BREAST-Q version 2.0. A guide for researchers and clinicians
.
Meml Sloan Kettering Cancer Cent
;
2017
; p.
1
26
.
24.
Clavien
PA
,
Barkun
J
,
De Oliveira
ML
,
Vauthey
JN
,
Dindo
D
,
Schulick
RD
, et al
.
The clavien-dindo classification of surgical complications: five-year experience
.
Ann Surg
.
2009
;
250
(
2
):
187
96
.
25.
Ogura
K
,
Yakoub
MA
,
Christ
AB
,
Fujiwara
T
,
Nikolic
Z
,
Boland
PJ
, et al
.
What are the minimum clinically important differences in SF-36 scores in patients with orthopaedic oncologic conditions
.
Clin Orthop Relat Res
.
2020
;
478
(
9
):
2148
58
.
26.
Lemay
KR
;
Tulloch
HE
,
Pipe
AL
,
Reed
JL
.
Establishing the minimal clinically important difference for the hospital anxiety and depression scale in patients with cardiovascular disease
.
J Cardiopulm Rehabil Prev
.
2019
;
39
(
6
).
E6
11
.
27.
Kang
H
.
Sample size determination and power analysis using the G*Power software
.
J Educ Eval Health Prof
.
2021
;
18
:
17
.
28.
Casals
M
,
Girabent-Farrés
M
,
Carrasco
JL
.
Methodological quality and reporting of generalized linear mixed models in clinical medicine (2000-2012): a systematic review
.
PLoS One
.
2014
;
9
(
11
):
e112653
10
.
29.
Sadok
N
,
Refaee
MS
,
Eltahir
Y
,
de Bock
GH
,
van Veen
MM
,
Werker
PMN
.
Quality of life 9-13 Years after autologous or alloplastic breast reconstruction
.
Which Breast Remains Best?
.
2020
;
21
.
30.
Kouwenberg
CAE
,
De Ligt
KM
,
Kranenburg
LW
,
Rakhorst
H
,
de Leeuw
D
,
Siesling
S
, et al
.
Long-term health-related quality of life after four common surgical treatment options for breast cancer and the effect of complications: a retrospective patient-reported survey among 1871 patients
.
Plast Reconstr Surg
.
2020
;
146
:
1
13
.
31.
Miyazawa
K
,
Satake
T
,
Muto
M
,
Tsunoda
Y
,
Koike
T
,
Narui
K
, et al
.
Delayed breast reconstruction with autologous free flap after radiation therapy: vascular complications and aesthetic outcomes
.
Breast Cancer
.
2024
;
31
(
5
):
798
806
.
32.
Li
R
,
Ranganath
B
.
Preoperative depression is an independent risk factor for short-term morbidities in autologous and implant-based breast reconstruction
.
J Plast Reconstr Aesthet Surg
.
2024
;
95
:
190
8
.
33.
Devalia
HL
,
Mansfield
L
.
Radiotherapy and wound healing
.
Int Wound J
.
2008
;
5
(
1
):
40
4
.
34.
Fobair
P
,
Stewart
SL
,
Chang
S
,
D’Onofrio
C
,
Banks
PJ
,
Bloom
JR
.
Body image and sexual problems in young women with breast cancer
.
Psychooncology
.
2006
;
15
(
7
):
579
94
.
35.
Santosa
KB
,
Qi
J
,
Kim
HM
,
Hamill
JB
,
Pusic
AL
,
Wilkins
EG
.
Effect of patient age on outcomes in breast reconstruction: results from a multicenter prospective study
.
J Am Coll Surg
.
2016
;
223
(
6
):
745
54
.
36.
Tallroth
L
,
Mobargha
N
,
Velander
P
,
Becker
M
,
Klasson
S
.
Expander prosthesis and DIEP flaps in delayed breast reconstruction: sensibility, patient-reported outcome, and complications in a five-year randomised follow-up study
.
J Plast Surg Hand Surg
.
2023
;
58
:
101
9
.
37.
Naoum
GE
,
Ioakeim
MI
,
Shui
AM
,
Salama
L
,
Colwell
A
,
Ho
AY
, et al
.
Radiation modality (Proton/Photon), timing, and complication rates in patients with breast cancer receiving 2-stages expander/implant reconstruction
.
Pract Radiat Oncol
.
2022
;
12
(
6
):
475
86
.
38.
Haussmann
J
,
Budach
W
,
Corradini
S
,
Krug
D
,
Jazmati
D
,
Tamaskovics
B
, et al
.
Comparison of adverse events in partial: or whole breast radiotherapy: investigation of cosmesis, toxicities and quality of life in a meta: analysis of randomized trials
.
Radiat Oncol
.
2023
;
18
:
181
23
.
39.
Nelson
JA
,
Cordeiro
PG
,
Polanco
T
,
Shamsunder
MG
,
Patel
A
,
Allen
RJ
Jr
, et al
.
Association of radiation timing with long-term satisfaction and health-related quality of life in prosthetic breast reconstruction
.
Plast Reconstr Surg
.
2022
;
150
(
1
):
32E
41E
.
40.
Schmidt
ME
,
Scherer
S
,
Wiskemann
J
,
Steindorf
K
.
Return to work after breast cancer: the role of treatment-related side effects and potential impact on quality of life
.
Eur J Cancer Care
.
2019
;
28
(
4
):
e13051
11
.
41.
Dorfman
R
,
Saadat
S
,
Gupta
N
,
Roostaeian
J
,
Da Lio
A
.
The COVID-19 pandemic and plastic surgery: literature review, ethical analysis, and proposed guidelines
.
Plast Reconstr Surg
.
2020
;
146
(
4
):
482E
93E
.
42.
Taghioff
SM
,
Slavin
BR
,
Mehra
S
,
Holton
T
,
Singh
D
.
Risk stratification of surgical-site outcomes by BMI and flap type in autologous breast reconstruction
.
J Plast Reconstr Aesthet Surg
.
2023
;
80
:
115
25
.
43.
Lem
M
,
Kim
JKH
,
Pham
JT
,
Tang
CJ
.
Effect of the COVID-19 pandemic on global interest in plastic surgery
.
JPRAS Open
.
2023
;
37
:
63
71
.
44.
Ghanouni
A
,
Thompson
P
,
Losken
A
.
Outcomes of the Goldilocks technique in high-risk breast reconstruction patients
.
Plast Reconstr Surg
.
2023
;
152
(
4S
):
35S
40S
.
45.
Setit
A
,
Bela
K
,
Khater
A
,
Elzahaby
I
,
Hossam
A
,
Hamed
E
.
Nipple sparing Goldilocks mastectomy, A new modification of the original technique
.
Eur J Breast Heal
.
2023
;
19
(
2
):
172
6
.
46.
Schmidt
JL
,
Wetzel
CM
,
Lange
KW
,
Heine
N
,
Ortmann
O
.
Patients’ experience of breast reconstruction after mastectomy and its influence on postoperative satisfaction
.
Arch Gynecol Obstet
.
2017
;
296
(
4
):
827
34
.